Cas:1948-71-6 AC-TYR-NH2 manufacturer & supplier

We serve Chemical Name:AC-TYR-NH2 CAS:1948-71-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

AC-TYR-NH2

Chemical Name:AC-TYR-NH2
CAS.NO:1948-71-6
Synonyms:ac-tyr-nh2;EINECS 217-756-4;Benzenepropanamide, N-acetyl-α-amino-4-hydroxy-, (αS)-;N-Acetyl-L-tyrosinamide
Molecular Formula:C11H14N2O3
Molecular Weight:222.240
HS Code:2924299090

Physical and Chemical Properties:
Melting point:223-225ºC(lit.)
Boiling point:459.5±40.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.577
PSA:92.42000
Exact Mass:222.100449
LogP:-0.88

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like ac-tyr-nh2 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-Acetyl-L-tyrosinamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 217-756-4 Use and application,N-Acetyl-L-tyrosinamide technical grade,usp/ep/jp grade.


Related News: As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters. AC-TYR-NH2 manufacturer Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease. AC-TYR-NH2 supplier Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high. AC-TYR-NH2 vendor Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease. AC-TYR-NH2 factory Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high.